These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 20875047)

  • 1. The multiplicity of action of cannabinoids: implications for treating neurodegeneration.
    Gowran A; Noonan J; Campbell VA
    CNS Neurosci Ther; 2011 Dec; 17(6):637-44. PubMed ID: 20875047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoids.
    Grotenhermen F
    Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):507-30. PubMed ID: 16266285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
    Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
    Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier.
    Vendel E; de Lange EC
    Neuromolecular Med; 2014 Sep; 16(3):620-42. PubMed ID: 24929655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The seek of neuroprotection: introducing cannabinoids.
    Martínez-Orgado J; Fernández-López D; Lizasoain I; Romero J
    Recent Pat CNS Drug Discov; 2007 Jun; 2(2):131-9. PubMed ID: 18221224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
    Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O
    ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid system and multiple sclerosis.
    Baker D; Pryce G
    Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids in depressive disorders.
    Poleszak E; Wośko S; Sławińska K; Szopa A; Wróbel A; Serefko A
    Life Sci; 2018 Nov; 213():18-24. PubMed ID: 30290188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review.
    Velayudhan L; Van Diepen E; Marudkar M; Hands O; Suribhatla S; Prettyman R; Murray J; Baillon S; Bhattacharyya S
    Curr Pharm Des; 2014; 20(13):2218-30. PubMed ID: 23829360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and Alzheimers diseases.
    Abd-Nikfarjam B; Dolati-Somarin A; Baradaran Rahimi V; Askari VR
    Biofactors; 2023; 49(3):560-583. PubMed ID: 36637897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases.
    Pérez-Olives C; Rivas-Santisteban R; Lillo J; Navarro G; Franco R
    Adv Exp Med Biol; 2021; 1264():81-92. PubMed ID: 33332005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
    de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
    Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system as a target for the treatment of motor dysfunction.
    Fernández-Ruiz J
    Br J Pharmacol; 2009 Apr; 156(7):1029-40. PubMed ID: 19220290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury.
    Zhang M; Martin BR; Adler MW; Razdan RK; Ganea D; Tuma RF
    Neuroscience; 2008 Mar; 152(3):753-60. PubMed ID: 18304750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection.
    De Filippis D; Steardo A; D'Amico A; Scuderi C; Cipriano M; Esposito G; Iuvone T
    ScientificWorldJournal; 2009 Mar; 9():229-35. PubMed ID: 19347234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.
    Croxford JL; Pryce G; Jackson SJ; Ledent C; Giovannoni G; Pertwee RG; Yamamura T; Baker D
    J Neuroimmunol; 2008 Jan; 193(1-2):120-9. PubMed ID: 18037503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of cannabinoids on generic traits of neurodegeneration.
    Fagan SG; Campbell VA
    Br J Pharmacol; 2014 Mar; 171(6):1347-60. PubMed ID: 24172185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
    De Petrocellis L; Di Marzo V
    J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.
    Basavarajappa BS; Nixon RA; Arancio O
    Mini Rev Med Chem; 2009 Apr; 9(4):448-62. PubMed ID: 19356123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.